No Data
Strong Week for OptimizeRx (NASDAQ:OPRX) Shareholders Doesn't Alleviate Pain of Three-year Loss
OptimizeRx (OPRX) Was Downgraded to a Hold Rating at Stifel Nicolaus
OptimizeRx CEO William Febbo Resigns, Leadership Transition Planned
OptimizeRx Shares Are Trading Lower After RBC Capital Downgraded the Stock From Outperform to Sector Perform and Cut Its Price Target From $7 to $6.
RBC Capital Downgrades OptimizeRx(OPRX.US) to Hold Rating, Cuts Target Price to $6
RBC Downgrades OptimizeRx to Sector Perform From Outperform, Cuts Price Target to $6 From $7
MARKET-TEST-DUMMY OP :